SCHEMBL26601634

SCHEMBL26601634

Cc1cc(C(C)(C)C)ccc1-c1cc(OCc2ccccc2)c(N)c(C)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.43
ATP4A P20648 2/20 0.42
ATP4B P51164 2/20 0.42
STAT3 P40763 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
RXRA P19793 1/20 0.37
RXRB P28702 1/20 0.37
RXRG P48443 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
LTA4H P09960 1/20 0.36
MAPK14 Q16539 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26601938 0.86 MRGPRX4 (0.43) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26601643 0.86 MRGPRX4 (0.43) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26601687 0.85 MRGPRX4 (0.40) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26706194 0.84 MRGPRX4 (0.44) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL31747877 0.84 MRGPRX4 (0.44) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26601676 0.84 MRGPRX4 (0.51) MRGPRX4STAT3HTTSMN1; SMN2L3MBTL1
SCHEMBL26601774 0.84 MRGPRX4 (0.43) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26601626 0.83 MRGPRX4 (0.43) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26705979 0.82 MRGPRX4 (0.40) MRGPRX4ATP4AATP4BSTAT3HTT
SCHEMBL26706913 0.82 MRGPRX4 (0.40) MRGPRX4ATP4AATP4BSTAT3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 US disclosed
EP-4511117-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 EP disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed
WO-2023205465-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388541-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN1B, CLIC1, HCN1 MRGPRX4 999/4885ATP4A 197/4885ATP4B 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.